Department of Gynaecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
Cancer Biomark. 2017 Dec 12;21(1):97-104. doi: 10.3233/CBM-170305.
Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis.
We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values.
CCL18 serum concentrations were detected by ELISA in 187 patients with EOC, 126 patients with benign PMs, and 118 healthy controls. CCL18 serum levels were analyzed in the context of patients' clinicopathological information, and ROC analyses were performed to determine the effect of CCL18 on distinguishing benign and malignant PMs. The ability of CCL18 to serve as an EOC biomarker was compared with CA125. Further survival analyses were carried out to assess the prognostic value of CCL18 in EOC patients.
Mean serum CCL18 levels were elevated in benign PM patients and were even higher in EOC patients than in healthy controls; furthermore, high CCL18 expression was associated with worse International Federation of Gynecology and Obstetrics (FIGO) staging and predicted a poorer survival of the patient. When compared with CA125, although the sensitivity and negative predictive values (NPV) of serum CCL18 were lower, its specificity and positive predictive values (PPV) were higher.
Serum CCL18 was elevated in patients with EOC and could serve as a new tumor biomarker, which also predicted a poor survival of the patient.
早期发现和鉴别诊断盆腔肿块（PM）对于改善上皮性卵巢癌（EOC）患者的预后至关重要。CC 趋化因子配体 18（CCL18）被报道为一种趋化因子介导的肿瘤相关炎症，可以在血清中检测到，并且可能与癌症患者的预后相关。
本研究旨在探讨 CCL18 水平与 EOC 患者临床特征的关系，并探讨其诊断和预后价值。
采用 ELISA 法检测 187 例 EOC 患者、126 例良性 PM 患者和 118 例健康对照者的 CCL18 血清浓度。分析 CCL18 血清水平与患者临床病理信息的关系，并进行 ROC 分析，以确定 CCL18 对鉴别良恶性 PM 的作用。将 CCL18 作为 EOC 生物标志物的能力与 CA125 进行比较。进一步进行生存分析，以评估 CCL18 在 EOC 患者中的预后价值。
良性 PM 患者血清 CCL18 水平升高，EOC 患者血清 CCL18 水平甚至高于健康对照组；此外，高 CCL18 表达与国际妇产科联合会（FIGO）分期较差相关，并预示患者预后较差。与 CA125 相比，虽然血清 CCL18 的敏感性和阴性预测值（NPV）较低，但特异性和阳性预测值（PPV）较高。
EOC 患者血清 CCL18 水平升高，可作为一种新的肿瘤标志物，也预示着患者预后较差。
